Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Center Study to Assess the Safety and Efficacy of the Fully Human Anti-TNF-α Monoclonal Antibody Adalimumab (D2E7) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis

NCT00448383 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00448383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00448383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Center Study to Assess the Safety and Efficacy of the Fully Human Anti-TNF-α Monoclonal Antibody Adalimumab (D2E7) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis
Lead sponsor
Abbott
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2002
Completion date
Not reported
Enrollment
6,610 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis